Impact BioMedical Inc.
IBO
$0.43
-$0.01-1.60%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 67.79% | 130.59% | 53.32% | 34.68% | -6.57% |
| Depreciation & Amortization | 1.61% | 1.07% | 0.18% | -0.09% | 0.18% |
| Other Operating Expenses | 177.64% | 213.93% | 150.00% | 46.61% | 847.06% |
| Total Operating Expenses | 9.50% | 15.44% | -8.96% | -15.62% | -6.58% |
| Operating Income | -8.82% | -15.25% | 8.96% | 15.62% | 6.58% |
| Income Before Tax | -4,125.96% | -790.95% | -449.07% | -461.27% | 113.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4,128.96% | -791.71% | -449.79% | -462.02% | 116.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -25.40% | -33.33% | -61.46% | -75.40% | -72.61% |
| Net Income | -3,906.29% | -805.70% | -460.79% | -494.61% | 118.48% |
| EBIT | -8.82% | -15.25% | 8.96% | 15.62% | 6.58% |
| EBITDA | 14.55% | -15.21% | 8.97% | 15.66% | -0.52% |
| EPS Basic | -2,742.90% | -1,242.26% | -1,180.85% | -2,506.48% | 259.60% |
| Normalized Basic EPS | -1,170.28% | -339.91% | 116.56% | 147.13% | 360.06% |
| EPS Diluted | -2,022.83% | -1,292.89% | -1,231.54% | -2,451.64% | -81.58% |
| Normalized Diluted EPS | -835.85% | -468.73% | -69.09% | -237.03% | -197.41% |
| Average Basic Shares Outstanding | -21.41% | -60.61% | -75.03% | -82.15% | -78.37% |
| Average Diluted Shares Outstanding | -60.54% | -10.20% | -41.51% | -57.05% | -56.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |